ArticlePediatric nephrology (Berlin, Germany)2026
Clinical and molecular spectrum of primary hyperoxaluria type 1 in Tunisia: pediatric presentation and minimum observed prevalence.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder caused by pathogenic variants in the AGXT gene. In regions with a high prevalence of consanguinity, the burden of PH1 is expected to be increased; however, data on its epidemiology in Tunisia remain scarce. This study aimed to estimate the minimum observed clinical prevalence of PH1 in Tunisia, to assess the expected genetic burden based on published pathogenic allele frequency data, and to describe the clinical and molecular spectrum of the disease in this cohort.
methodsWe retrospectively analyzed genetically confirmed PH1 patients referred to a major national tertiary referral center in Tunisia between 2011 and 2025, in whom molecular diagnosis was established by systematic Sanger sequencing of the AGXT gene. The minimum observed clinical prevalence was estimated using national population data. The expected genetic burden was derived using Hardy-Weinberg equilibrium based on published gene-based pathogenic AGXT allele frequency estimates from large population databases (gnomAD). A sensitivity analysis incorporating population-level consanguinity was performed.
resultsA total of 104 PH1 patients from 55 unrelated families were identified. Most patients presented during childhood (at least 77%), mainly with nephrolithiasis or nephrocalcinosis, while kidney failure (CKD stage 5) was already present in at least half of the probands. The minimum observed clinical prevalence of PH1 in Tunisia was estimated at 8.7 cases per million inhabitants. By contrast, gene-based estimates suggested that approximately 200-300 individuals would be expected to be affected in an outbred population of 12 million. A marked founder effect was observed for the c.731 T>C (p.Ile244Thr) variant.
conclusionsPH1 represents a significant cause of pediatric kidney disease in Tunisia and is likely underdiagnosed. These findings support the need for increased clinical awareness, early genetic testing, and timely diagnosis to optimize patient management in the era of disease-modifying therapies.
Indexed as
Identifiers
42002641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.